This technology is a high-pressure injector device enabling rapid delivery of viscous drugs and can be used for self-administered therapies.
Self-administered therapies, particularly for chronic conditions, can greatly improve patients’ quality of life. However, many new drugs such as antibodies and hormones are very viscous and difficult to administer due to their high molecular weights. Currently available injection devices for high-speed delivery of viscous drugs use mechanical springs that are noisy and uncomfortable, ultimately reducing patient adherence to injection schedules. There is a need for injector devices capable of rapid delivery of viscous drugs, in order to improve patient comfort and adherence to life-saving therapies.
This technology is an injection device that uses a water-sensitive biochemical actuation method for high-speed delivery of viscous drugs with enhanced comfort. The device generates a high-pressure response through a triggered actuation mechanism, which results in rapid drug delivery. Unlike currently available injector devices, this technology eliminates the need for noisy and uncomfortable mechanical springs, and does not require dilution of viscous drugs. This technology has the potential to significantly enhance drug delivery of viscous therapeutics, improve patient comfort and adherence to treatment, and can be used for delivery of other highly viscous materials such as adhesives and sealants.
IR CU18187
Licensing Contact: Dovina Qu
